Free Trial

Aktis Oncology (AKTS) Insider Trading & Ownership

Aktis Oncology logo
$18.27 -0.33 (-1.77%)
Closing price 04:00 PM Eastern
Extended Trading
$18.25 -0.02 (-0.11%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aktis Oncology (NASDAQ:AKTS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.30%
Number Of
Insiders Buying
(Last 12 Months)
5
Amount Of
Insider Buying
(Last 12 Months)
$110.12M
Number Of
Insiders Selling
(Last 12 Months)
0
Get AKTS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Aktis Oncology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKTS Insider Buying and Selling by Quarter

Aktis Oncology Insider and Congressional Trades History

Transaction DateInsiderBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/12/2026
Ansbert Gadicke
Major Shareholder
Buy1,112,777$18.00$20,029,986.00  
1/12/2026
Bioventures 2018 L.P. Mpm
Major Shareholder
Buy1,112,777$18.00$20,029,986.00  
1/12/2026
Ecor1 Capital, Llc
Director
Buy2,222,222$18.00$39,999,996.00  
1/12/2026Buy835,000$18.00$15,030,000.00  
1/12/2026
Vida Ventures Ii, Llc
Major Shareholder
Buy835,000$18.00$15,030,000.00  
(Data available from 1/1/2013 forward)

AKTS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Aktis Oncology includes Ansbert Gadicke, Bioventures 2018 L.P. Mpm, Ecor1 Capital, Llc, Helen Susan Kim, and Vida Ventures Ii, Llc. Learn more on insiders at AKTS.

3.30% of Aktis Oncology stock is owned by insiders. Learn more on AKTS's insider holdings.

The following insiders have purchased AKTS shares in the last 24 months: Ansbert Gadicke ($20,029,986.00), Bioventures 2018 L.P. Mpm ($20,029,986.00), Ecor1 Capital, Llc ($39,999,996.00), Helen Susan Kim ($15,030,000.00), and Vida Ventures Ii, Llc ($15,030,000.00).

Insiders have purchased a total of 6,117,776 AKTS shares in the last 24 months for a total of $110,119,968.00 bought.



This page (NASDAQ:AKTS) was last updated on 5/11/2026 by MarketBeat.com Staff.
From Our Partners